Sanofi ROA 2006-2018 | SNY

Current and historical return on assets (ROA) values for Sanofi (SNY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Sanofi ROA for the three months ending March 31, 2018 was 9.78%.
Sanofi ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-03-31 $4.71B $0.00B 8.37%
2017-12-31 $9.53B $112.83B 16.96%
2017-09-30 $9.90B $0.00B 17.37%
2017-06-30 $9.92B $112.08B 17.41%
2017-03-31 $10.09B $0.00B 17.71%
2016-12-31 $5.21B $115.83B 9.15%
2016-09-30 $6.19B $0.00B 22.10%
2016-06-30 $5.76B $111.96B 10.46%
2016-03-31 $5.52B $0.00B 9.48%
2015-09-30 $4.90B $0.00B 5.45%
2015-06-30 $4.59B $108.32B 3.75%
2014-06-30 $5.57B $124.45B 5.83%
2013-06-30 $6.39B $126.66B 6.44%
2012-06-30 $8.61B $130.75B 12.74%
2012-03-31 $8.56B $0.00B 12.10%
2011-12-31 $9.33B $139.51B 13.20%
2011-09-30 $8.04B $0.00B 12.53%
2011-06-30 $7.45B $143.31B 11.62%
2011-03-31 $8.22B $0.00B 14.73%
2010-12-31 $8.24B $113.22B 14.76%
2010-09-30 $9.30B $0.00B 16.78%
2010-06-30 $10.37B $110.06B 18.71%
2010-03-31 $11.38B $0.00B 21.05%
2009-12-31 $10.99B $111.64B 20.34%
2009-09-30 $9.57B $0.00B 18.20%
2009-06-30 $8.26B $104.55B 15.69%
2009-03-31 $7.76B $0.00B 14.67%
2008-12-31 $7.76B $105.92B 14.69%
2008-09-30 $9.72B $0.00B 19.04%
2008-06-30 $10.42B $105.54B 20.42%
2008-03-31 $9.21B $0.00B 18.44%
2007-12-31 $8.40B $98.57B 16.82%
2007-09-30 $6.95B $0.00B 13.97%
2007-06-30 $6.45B $101.22B 12.98%
2007-03-31 $7.18B $0.00B 14.36%
2006-12-31 $6.99B $97.69B 13.97%
2006-09-30 $6.79B $0.00B 12.91%
2006-06-30 $6.95B $102.44B 13.22%
2006-03-31 $6.66B $0.00B 12.08%
2005-12-31 $5.54B $107.92B 10.05%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $112.613B $39.599B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.162B 18.20
Pfizer (PFE) United States $259.069B 14.60
Novartis AG (NVS) Switzerland $204.655B 17.49
Merck (MRK) United States $201.163B 17.43
AbbVie (ABBV) United States $132.702B 11.78
Eli Lilly (LLY) United States $119.057B 20.93
Novo Nordisk (NVO) Denmark $107.980B 17.54
AstraZeneca (AZN) United Kingdom $105.090B 13.05
GlaxoSmithKline (GSK) United Kingdom $102.669B 13.80
Bristol-Myers Squibb (BMY) United States $85.837B 14.14